Resources

Medical professional

Around 216,000 people in the UK are living with hepatitis C so it is important that all medical professionals have access to the latest training, information and advice on hepatitis C management.  Find here links to relevant materials for clinicians, nurses, GPs, prison healthcare staff and other medical professionals.

 

Showing 41 to 50 of 349 resources

  • Detecting & managing hepatitis C in primary care: Supporting people through treatment
    This short film, aimed at GPs and others working in primary care, examines the support needs of people living with, and being treated for hepatitis C, the management of side effects, the promotion of harm reduction and positive lifestyle advice and the significance of integrated care and support for patients and carers.
    UK Apr 2015 Training, Tools & Templates Video
  • Detecting & managing hepatitis C in primary care: The impact and consequences of hepatitis C infection
    This short film, aimed at GPs and others working with primary care, covers the prevalence of undiagnosed hepatitis C, the growing public health burden of infection and the natural history and consequences of hepatitis C infection.
    UK Apr 2015 Training, Tools & Templates Video
  • Diagnosing viral hepatitis in the community: A 3-month pharmacy testing pilot
    This document sets out the findings of a 3 month pharmacy testing pilot.
    England Jan 2010 Case study, Reports & Research PDF
  • Drug-related infectious diseases in Europe
    This report from the European Monitoring Centre for Drugs and Drug Addiction provides an overview of infectious disease surveillance data, outbreak investigations, and prevention and control measures among people who inject drugs in Europe up to February 2019, including viral hepatitis.
    UK, Rest of World 16 Jul 2019 Reports & Research PDF
  • Drug-related infectious diseases in Europe
    This report provides an update on infectious diseases related to drug use in Europe for the period up to June 2016. It covers the most recent data both on infectious diseases among people who inject drugs in Europe, collected with the European Monitoring Centre for Drugs and Drug Addiction Drug-related infectious diseases (DRID) indicator, and on the responses in the area. It includes highlights and new findings discussed during the DRID indicator’s annual expert meeting, held in Lisbon on 6–8 June 2016.
    Rest of World Reports & Research PDF
  • Drug-related infectious diseases in Europe: Update from the EMCDDA expert network, 2020
    This 2020 update on drug-related infectious diseases from the EMCDDA (European Monitoring Centre for Drugs and Drug Addiction) aims to provide a comprehensive overview of the current situation with regard to the epidemiological picture of drug-related infectious diseases in Europe up to January 2020. It highlights some recent innovative responses to the problem and argues that early diagnosis through testing as well as improving links to treatment and care are crucial steps towards reaching global health goals.
    UK, Rest of World Reports & Research, Strategy & Planning PDF
  • EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
    These EASL Clinical Practice Guidelines (CPGs) are intended to assist physicians and other healthcare providers, as well as patients and other interested individuals, in the clinical decision-making process by describing the optimal management of patients with acute and chronic HCV infections. These guidelines apply to therapies that are approved at the time of their publication.
    UK, Rest of World 2014 Training, Reports & Research, Tools & Templates PDF
  • EASL Recommendations on Treatment of Hepatitis C 2016
    These EASL Recommendations on Treatment of Hepatitis C are intended to assist physicians and other healthcare providers, as well as patients and other interested individuals, in the clinical decision-making process by describing the current optimal management of patients with acute and chronic HCV infections. These recommendations apply to therapies that have been approved by the European Medicines Agency and other national European agencies at the time of their publication.
    Rest of World Sep 2016 Other, Reports & Research PDF
  • EASL Recommendations on Treatment of Hepatitis C: 2014
    These EASL Recommendations on Treatment of Hepatitis C are intended to assist physicians and other healthcare providers, as well as patients and other interested individuals, in the clinical decisionmaking process by describing the optimal management of patients with acute and chronic HCV infections. These guidelines apply to therapies that will be approved within less than 6 months at the time of their publication.
    UK Apr 2014 Reports & Research, Tools & Templates, Strategy & Planning PDF
  • East Midlands Specialised Commissioning Group Commissioning Policy for Hepatitis C Treatments
    This commissioning policy paper was produced for the treatment of patients with Hepatitis C in the East Midlands, with the aim of providing and ensuring equity, consistency and clarity in approach to treatment across the region. The document sets out the position of East Midlands Specialised Commissioning Group PCTs in respect of treatment for Hepatitis C for its current and future patients, outlining the treatment regimens for the various different genotypes of Hepatitis C using combination therapy (pegylated interferon alpha and weight-based ribavirin).
    East Midlands Jun 2009 Case study, Tools & Templates, Strategy & Planning PDF

Pages